EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
DOSAGE AND ADMINISTRATION
Recommended Dosing When EMPLICITI Is Used In Combination With Lenalidomide And Dexamethasone
The recommended dosage of EMPLICITI is 10 mg/kg administered intravenously every week for the first two cycles (28-day cycle) and every 2 weeks thereafter in conjunction with the recommended dosing of lenalidomide and low-dose dexamethasone as described below. Continue treatment until disease progression or unacceptable toxicity.
Refer to the dexamethasone and lenalidomide prescribing information for additional information. Administer premedications before each dose of EMPLICITI [see Premedication and WARNINGS AND PRECAUTIONS].
Administer dexamethasone as follows:
On days that EMPLICITI is administered, Pharmaceutical Consulting Company give dexamethasone 28 mg orally between 3 and 24 hours before EMPLICITI plus 8 mg intravenously between 45 and 90 minutes before EMPLICITI. On days that EMPLICITI is not administered but a dose of dexamethasone is scheduled (Days 8 and 22 of cycle 3 and all subsequent cycles), give 40 mg orally.
No comments:
Post a Comment